November 9th webcast to include a review of third quarter 2023 financial results
EMERYVILLE, Calif.–(BUSINESS WIRE)–$OABI #OABI—OmniAb, Inc. (Nasdaq: OABI) announces the agenda for its Research & Technology virtual event to be held on Thursday, November 9th beginning at 11:00 a.m. Eastern time. The two-hour event will include an update on the company’s technology offerings, a review of third quarter financial results, which will be announced earlier that morning, and a Q&A session.
The agenda for the event is as follows:
- Business Overview and Updates – Matt Foehr, Chief Executive Officer
- Creating Value for our Partners – Todd Pettingill, Vice President, Business Development and Strategy
- Introducing the OmnidAb™ Technology – Bill Harriman, Ph.D., Sr. Vice President, Antibody Discovery
- Enhancing Discovery with OmniDeep™ – Bob Chen, Ph.D., Sr. Director, Discovery Systems
- The Ion Channel Opportunity – Doug Krafte, Ph.D., Sr. Vice President, Ion Channels/Transporters
- Financial Updates – Kurt Gustafson, Chief Financial Officer
Interested parties are requested to register in advance by clicking here. The live and archived webcast, along with speaker slides, will be available on the Investors portion of OmniAb’s website.
About OmniAb®
OmniAb’s discovery platform provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence™ (BI) of our proprietary transgenic animals, including OmniRat®, OmniChicken® and OmniMouse® that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic® (transgenic rat) and OmniClic® (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur™ features unique structural attributes of cow antibodies for complex targets. We believe the OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms to identify fully human antibodies with superior performance and developability characteristics. These proprietary technologies are joined with and leverage OmniDeep™, which is a suite of in silico tools for therapeutic discovery and optimization that are woven throughout OmniAb’s various technologies and capabilities. Additionally, an established core competency focused on ion channels and transporters further differentiates OmniAb’s technology and creates opportunities in many emerging target classes. OmniAb antibodies have been leveraged across modalities, including bispecific antibodies, antibody-drug conjugates and others.
The OmniAb suite of technologies span from BI-powered repertoire generation to cutting-edge antibody discovery and optimization offering a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry.
For more information, please visit www.omniab.com.
Contacts
OmniAb, Inc.
Neha Singh, Ph.D.
investors@OmniAb.com
X (Twitter) @OmniAbTech
(510) 768-7760